Hasenmajer, Valeria http://orcid.org/0000-0003-4301-6662
Ferrigno, Rosario http://orcid.org/0000-0002-8172-2405
Minnetti, Marianna http://orcid.org/0000-0002-9091-2809
Pellegrini, Bianca http://orcid.org/0000-0002-0496-8997
Isidori, Andrea M. http://orcid.org/0000-0002-9037-5417
Lenzi, Andrea http://orcid.org/0000-0002-7711-0465
Salerno, Mariacarolina http://orcid.org/0000-0003-1310-3300
Cappa, Marco http://orcid.org/0000-0001-5647-7519
Chan, Li http://orcid.org/0000-0001-5146-8242
De Martino, Maria Cristina http://orcid.org/0000-0003-3354-009X
Savage, Martin O. http://orcid.org/0000-0001-7902-3376
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017HRTZYA, PRIN 2017N8CK4K)
Article History
Accepted: 3 January 2023
First Online: 10 February 2023
Declarations
:
: VH, RF, MM, BP, AL, MCS, MC, MCDM, MOS have nothing to disclose. A.M.I. does consultancy for Novartis, Takeda, Recordati, and Sandoz companies and has received research grants and honoraria from Shire, IPSEN, and Pfizer company. LC does consultancy for OMass therapeutics.
: Not applicable.
: Not applicable.
: The authors have no conflicts of interest to report.